Synergism of Anti-CGRP Monoclonal Antibodies and OnabotulinumtoxinA in the Treatment of Chronic Migraine: A Real-World Retrospective Chart Review

被引:0
作者
Amira Salim
Elise Hennessy
Claire Sonneborn
Olivia Hogue
Sudipa Biswas
MaryAnn Mays
Aarushi Suneja
Zubair Ahmed
Ignacio F. Mata
机构
[1] Case Western Reserve University,Department of Molecular Medicine, Cleveland Clinic Lerner College of Medicine
[2] Cleveland Clinic,Genomic Medicine Institute, Lerner Research Institute
[3] Penn State Health Milton S. Hershey Medical Center,Neuroscience Institute
[4] Cleveland Clinic,Quantitative Health Sciences, Lerner Research Institute
来源
CNS Drugs | 2024年 / 38卷
关键词
D O I
暂无
中图分类号
学科分类号
摘要
引用
收藏
页码:481 / 491
页数:10
相关论文
共 113 条
[1]  
Burch RC(2019)Migraine Neurol Clin 37 631-649
[2]  
Buse DC(2024)The World Health Organization Intersectoral Global Action Plan on Epilepsy and Other Neurological Disorders and the headache revolution: from headache burden to a global action plan for headache disorders J Headache Pain 25 4-1041
[3]  
Lipton RB(2023)Rethinking headache as a global public health case model for reaching the SDG 3 HEALTH by 2030 J Headache Pain 24 140-434
[4]  
Leonardi M(2009)Barriers to satisfactory migraine outcomes. What have we learned, where do we stand? Headache 49 1028-1037
[5]  
Martelletti P(2017)Safety and efficacy of erenumab for preventive treatment of chronic migraine: a randomised, double-blind, placebo-controlled phase 2 trial Lancet Neurol 16 425-2122
[6]  
Burstein R(2018)ARISE: a phase 3 randomized trial of erenumab for episodic migraine Cephalalgia 38 1026-254
[7]  
Martelletti P(2018)Galcanezumab in chronic migraine: the randomized, double-blind, placebo-controlled REGAIN study Neurology 75 1080-100
[8]  
Leonardi M(2018)Evaluation of galcanezumab for the prevention of episodic migraine: the EVOLVE-1 randomized clinical trial JAMA Neurol 377 2113-287
[9]  
Ashina M(2017)Fremanezumab for the preventive treatment of chronic migraine N Engl J Med 40 241-217
[10]  
Bigal M(2020)Eptinezumab in episodic migraine: a randomized, double-blind, placebo-controlled study (PROMISE-1) Cephalalgia 23 67-187